Following Alexion's Q1 results, Oppenheimer analyst Christopher Marai views weakness from its Soliris headwinds in Latin America as a buying opportunity while the metabolic portfolio drives 2016-2017 growth. The company reported Soliris revenue below expectations, but Strensiq revenue above estimates, the analyst tells investors in a research note. Marai believes a "strong" Strensiq launch should drive growth in 2016, and Kanuma should drive growth in 2017, with Soliris growth steady in core territories and competition still far out. The analyst reiterates an Outperform rating and $228 price target on the shares.